Small Intestinal Fungal Overgrowth

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. Importantly, whether eradication or its treatment leads to resolution of symptoms remains unclear; at present, a 2–3-week course of antifungal therapy is recommended and may be effective in improving symptoms, but evidence for eradication is lacking.

Original languageEnglish (US)
JournalCurrent Gastroenterology Reports
Volume17
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Small Intestine
Eructation
Candidiasis
Proton Pump Inhibitors
Dyspepsia
Immunocompromised Host
Nausea
Diarrhea
Healthy Volunteers
Fungi
Gases
Steroids
Anti-Bacterial Agents
Therapeutics

Keywords

  • Diagnosis
  • Duodenal culture
  • Fungal overgrowth
  • Review
  • Small intestine
  • Symptoms
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Small Intestinal Fungal Overgrowth. / Erdogan, Askin; Rao, Satish Sanku Chander.

In: Current Gastroenterology Reports, Vol. 17, No. 4, 01.04.2015.

Research output: Contribution to journalArticle

@article{17b4cfb4c45d4d8d9311835bed9a0431,
title = "Small Intestinal Fungal Overgrowth",
abstract = "Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 {\%} (24/94) and 25.3 {\%} (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. Importantly, whether eradication or its treatment leads to resolution of symptoms remains unclear; at present, a 2–3-week course of antifungal therapy is recommended and may be effective in improving symptoms, but evidence for eradication is lacking.",
keywords = "Diagnosis, Duodenal culture, Fungal overgrowth, Review, Small intestine, Symptoms, Treatment",
author = "Askin Erdogan and Rao, {Satish Sanku Chander}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s11894-015-0436-2",
language = "English (US)",
volume = "17",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Small Intestinal Fungal Overgrowth

AU - Erdogan, Askin

AU - Rao, Satish Sanku Chander

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. Importantly, whether eradication or its treatment leads to resolution of symptoms remains unclear; at present, a 2–3-week course of antifungal therapy is recommended and may be effective in improving symptoms, but evidence for eradication is lacking.

AB - Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent studies showed that 26 % (24/94) and 25.3 % (38/150) of a series of patients with unexplained GI symptoms had SIFO. The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea, and gas. The underlying mechanism(s) that predisposes to SIFO is unclear but small intestinal dysmotility and use of proton pump inhibitors has been implicated. However, further studies are needed; both to confirm these observations and to examine the clinical relevance of fungal overgrowth, both in healthy subjects and in patients with otherwise unexplained GI symptoms. Importantly, whether eradication or its treatment leads to resolution of symptoms remains unclear; at present, a 2–3-week course of antifungal therapy is recommended and may be effective in improving symptoms, but evidence for eradication is lacking.

KW - Diagnosis

KW - Duodenal culture

KW - Fungal overgrowth

KW - Review

KW - Small intestine

KW - Symptoms

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84925950099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925950099&partnerID=8YFLogxK

U2 - 10.1007/s11894-015-0436-2

DO - 10.1007/s11894-015-0436-2

M3 - Article

VL - 17

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 4

ER -